PAVBLU™ (aflibercept-ayyh) is indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).
PAVBLU™ (aflibercept-ayyh) is indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration ...Read more
We created a 2-way communication flow between our Amgen® SupportPlus Customer Portal and commonly used platforms that can give you real-time access to information and resources.
When you prescribe PAVBLU™, you can USE AN INTEGRATED PORTAL PLATFORM TO:
Submit a Benefits Verification Form
View Your Patients’ Summary of Benefits
Assist Your Patients With Co-Pay Program Enrollment
Access Your Patients’ Co-Pay Program Status And Information
Visit the Amgen® SupportPlus Customer Portal, or an integrated portal platform
Our Amgen® SupportPlus representatives can assist with issues around patient coverage, prior authorizations, Amgen® SupportPlus Co-Pay Program, and more.
A Field Reimbursement Specialist can provide live or virtual coverage and access resources to support your patients that include:
The Amgen® SupportPlus Co-Pay Program may help eligible patients with private or commercial insurance lower their out-of-pocket costs.
*Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/copay-terms for full Terms and Conditions. Massachusetts and Rhode Island residents not eligible for in-office administration support.
Encourage your patients with private or commercial insurance to check eligibility and enroll at AmgenSupportPlus.com/copay
Visit AmgenSupportPlus.com or call 866-264-2778 Monday to Friday, 9:00 AM to 8:00 PM ET.
Available Amgen resources
OOP = out of pocket; VEGF = vascular endothelial growth factor.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see the full Prescribing Information for additional Important Safety Information.
PAVBLU™ (aflibercept-ayyh) is indicated for the treatment of: